IWWM-12: Management of IgM demyelinating neuropathy

During the 12th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-12), the Lymphoma Hub was pleased to speak to Shirley D’Sa, University College London, London, UK. We asked about management of IgM demyelinating neuropathy in patients with Waldenstrom's macroglobulinemia (WM).

In this interview, D’Sa discusses management of anti-myelin associated glycoprotein (MAG) neuropathy, a form of inflammatory neuropathy that impacts patients with IgM paraproteins. She highlights the efficacy of treatments, particularly the use of rituximab, while also acknowledging the complexities involved in determining the optimal timing for treatment and the metrics for assessing effectiveness. D’Sa emphasizes the importance of developing clinical metrics to effectively measure neuropathy and discusses the significance of a consensus panel aimed at enhancing treatment guidance for healthcare practitioners. 

This educational resource is independently supported by BeiGene. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.